VivoSeq
Other

Body Weight

0

Pipeline Programs↗

7

Active Trials↗

6

Companies Involved↗

Body Weight is an early-stage landscape with 0 programs across 6 companies. The most active players are Novo Nordisk, AstraZeneca, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalHanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

39

clinical trials

Completed25 · 64%
Unknown status4 · 10%
Recruiting4 · 10%
Active, not recruiting3 · 8%
Terminated3 · 8%

Clinical Trials

Trial Activity

39 trials

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT07253285·460 enrolled
Evaluation of Propofol Dosing Based on Total Body Weight Using Closes-loop Anaesthesia Delivery System
Recruiting·SSir Ganga Ram Hospital·Phase 4·NCT05305313·46 enrolled
Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI
Recruiting·IInstituto Mexicano del Seguro Social·Phase 4·NCT06602622·108 enrolled
Protein Supplementation Intervention on Body Weight
Recruiting·CChinese Academy of Sciences·N/A·NCT06989203·140 enrolled
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Active, not recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT05567796·3,400 enrolled
A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight
Active, not recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT07004322·20 enrolled
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Active, not recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT06388187·300 enrolled
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 4·NCT00778622·371 enrolled
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00189514·210 enrolled
Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index
Completed·Novartis logoNovartis·Phase 2·NCT02470403·181 enrolled
Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
Completed·LLaval University·Phase 4·NCT00353054·80 enrolled
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
Completed·Novo Nordisk logoNovo Nordisk·Phase 2·NCT06326060·355 enrolled
The Effect of Betahistine on Body Weight in Obese Subjects
Completed·OOBEcure Ltd.·Phase 2·NCT00409305·280 enrolled
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
Completed·Pfizer logoPfizer·Phase 2·NCT00542009·252 enrolled
The Effects of Rhus Coriaria L. on Body Weight
Completed·SShiraz University of Medical Sciences·N/A·NCT02754089·50 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)